P. Vigano, F. Parazzini, E. Somigliana, and P. Vercellini, Endometriosis: epidemiology and aetiological factors, Best Pract. Res. Clin. Obstet. Gynaecol, vol.18, pp.177-200, 2004.

, Recommandations pour la pratique clinique : prise en charge de l'endométriose, 2006.

S. Jenkins, D. L. Olive, and A. F. Haney, Endometriosis: pathogenetic implications of the anatomic distribution, Obstet. Gynecol, vol.67, pp.335-338, 1986.

P. Vercellini, G. Aimi, O. De-giorgi, S. Maddalena, S. Carinelli et al., Is cystic ovarian endometriosis an asymmetric disease?, Br. J. Obstet. Gynaecol, vol.105, pp.1018-1021, 1998.

A. Quibel, L. Puscasiu, L. Marpeau, and H. , Roman Les médecins traitants devant le défi du dépistage et de la prise en charge de l'endométriose: résultats d'une enquête, Gynécologie Obstétrique & Fertilité, vol.41, pp.372-380, 2013.

. Has and . Santé, Recommandations pour la pratique clinique : Prise en charge de l'endométriose -Décembre, 2017.

C. Poncelet and G. , Ducarme Prise en charge de l'endométriose : les bonnes pratiques de la coelioscopie diagnostique, Journal de Gynécologie Obstétrique et Biologie de la Reproduction, vol.36, pp.135-140, 2007.

P. Santulli, Increased serum CA 125 is a marker for severity of deep endometriosis, Journal of minimally invasive gynecology, vol.22, issue.2, pp.275-284, 2015.

E. Ozhan, . Kokcu, M. Yanik, and . Gunaydin, Investigation of diagnostic potentials of nine different biomarkers in Endometriosis, European Journal of Obstetrics & Gynecology and Reproductive Biology, vol.178, pp.128-133, 2014.

J. Yang, M. Sa, and M. Huang, The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemiluminescence immunoassay, Clin Biochem, vol.46, pp.1705-1713, 2013.

Y. Park, Y. Kim, E. Y. Lee, J. H. Lee, and H. S. Kim, Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostics performances for ovarian cancer, Int J Cancer, vol.130, pp.1136-1180, 2012.

M. T. Galgano, G. M. Hampton, F. Jr, and H. F. , Comprehensive analysis of HE4 expression in normal and malignant human tissues, Mod Pathol, vol.19, pp.847-53, 2006.

N. Bolstad, M. Oijordsbakken, K. Nustad, and J. Bjerner, Human epididymis protein 4 reference limits and natural variation in a Nordic reference population, Tumour Biol, vol.33, pp.141-149, 2012.

F. Braga, S. Ferraro, R. Mozzi, and M. Panteghini, The importance of individual biology in the clinical use of serum biomarkers for ovarian cancer, Clin Chem Lab Med, 2014.

R. G. Moore, Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age, American Journal of Obstetrics & Gynecology, vol.349, p.7, 2012.

J. M. Escudero, J. M. Auge, and X. Filella, Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases, Clin Chem, vol.57, pp.1534-1578, 2011.

B. Nagy, Z. T. Krasznai, and H. Balla, Elevated human epididymis protein 4 concentrations in chronic kidney disease, Ann Clin Biochem, vol.49, pp.377-80, 2012.

S. Ferraro, D. Schiumarini, and M. Panteghini, Human epididymis protein 4: Factors of variation, Clinica Chimica Acta, vol.438, pp.171-177, 2015.

M. Hallamaa, P. Suvitie, K. Huhtinen, J. Matomäki, and M. Poutanen, Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women, Gynecologic Oncology, vol.125, pp.667-672, 2012.

J. Lin, . Qin, and . Sangvatanakul, Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and metaanalysis, European Journal of Obstetrics & Gynecology and Reproductive Biology, vol.167, pp.81-85, 2013.

E. Lokich, Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass, Gynecol Oncol, vol.139, issue.2, pp.248-52, 2015.

R. G. Moore, Combining clinical assessment and the Risk of Ovarian Malignancy Algorithm for the prediction of ovarian cancer, Gynecol Oncol, vol.135, issue.3, pp.547-51, 2014.

I. Streuli, T. Fraisse, C. Pillet, V. Ibecheole, P. Bischof et al., Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids, Fertility and Sterility, vol.90, issue.2, pp.395-400, 2008.

D. Ziegler, D. Gayet, and V. , In women with endometriosis anti-Mullerian hormone levels are decreased only in those with previous endometrioma surgery, Hum Reprod, vol.27, issue.11, pp.3294-303, 2012.

D. Vet, A. Laven, J. S. De-jong, F. H. Themmen, A. P. Fauser et al., Anti-Müllerian hormone serum levels: a putative marker for ovarian aging, Fertility and Sterility, vol.77, pp.357-62, 2002.

A. P. Themmen, Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve, Human Reprod, vol.17, issue.12, pp.3065-71, 2002.

R. Fanchin, L. Schonäuer, C. Righini, J. Guibourdenche, R. Frydman et al., Serum anti müllerian hormone is more strongly related to ovarian follicular status than inhibin B, estradiol, FSH, and LH on day 3, Human Reprod, vol.18, issue.2, pp.323-327, 2003.

D. Seifer, D. Maclaughlin, B. Christian, B. Feng, and R. Et-shelden, Early follicular müllerianinhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles, Fertility and sterility, vol.77, pp.468-471, 2002.

J. Kitawaki, H. Ishihara, H. Koshiba, M. Kiyomizu, M. Teramoto et al., Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas, Hum Reprod, vol.20, issue.7, pp.1999-2003, 2005.

Q. Zeng, M. Liu, N. Zhou, L. Liu, and X. Song, Serum human epididymis protein 4 (HE4) may be a better tumor marker in early lung cancer, Clin Chim Acta, vol.455, pp.102-108, 2016.

D. Cheng, Y. Sun, and H. He, The diagnostic accuracy of HE4 in lung cancer: a meta-analysis, Dis Markers, vol.2015, p.352670, 2015.

U. R. Gündüz, A new marker for breast cancer diagnosis, human epididymis protein 4: A preliminary study, Mol Clin Oncol, vol.5, issue.2, pp.355-360, 2016.

S. Capriglione, Further insight into prognostic factors in endometrial cancer: the new serum biomarker HE4. Expert Rev Anticancer Ther, vol.17, pp.9-18, 2017.

T. Nikolova, R. Zivadinovic, N. Evtimovska, V. Klisarovska, M. Stanojevic et al., Diagnostic performance of human epididymis protein 4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women, J Obstet Gynaecol Res, vol.43, issue.12, pp.1870-1879, 2017.

J. Kaijser, T. Van-gorp, K. Van-hoorde, C. Van-holsbeke, A. Sayasneh et al., A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass, Gynecol Oncol, vol.129, issue.2, pp.377-83, 2013.

E. Piovano, C. Cavallero, L. Fuso, E. Viora, A. Ferrero et al., Diagnostic accuracy and cost-effectiveness of, vol.50, pp.395-403, 2017.

T. Van-gorp, J. Veldman, B. Van-calster, I. Cadron, K. Leunen et al., Vergote different strategies to triage women with adnexal masses: a prospective study

, Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses, Ultrasound Obstet Gynecol.I, vol.48, issue.11, pp.1649-56, 2012.

A. Pacchiarotti, P. Frati, G. N. Milazzo, A. Catalano, V. Gentile et al., Evaluation of serum anti-Mullerian hormone levels to assess the ovarian reserve in women with severe endometriosis, Eur J Obstet Gynecol Reprod Biol, vol.172, pp.62-66, 2014.

P. Carrarelli, A. L. Rocha, G. Belmonte, E. Zupi, M. S. Abrão et al., Increased expression of antimüllerian hormone and its receptor in endometriosis, Fertil Steril, vol.101, issue.5, pp.1353-1361, 2014.

R. Kucera, V. Babuska, Z. Ulcova-gallova, V. Kulda, and O. Topolcan, Follicular fluid levels of anti-Müllerian hormone, insulin-like growth factor 1 and leptin in women with fertility disorders, Syst Biol Reprod Med, vol.64, issue.3, pp.220-223, 2018.